Clinical trial
Combination Chemotherapy and Imatinib Mesylate in Treating Children With…
NCT00049569 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00049569 |
|---|---|
| Title | Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia |
| Official title | Intensive Induction Therapy for Children With Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Non-T, Non-B Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | cytarabine, methotrexate, vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, imatinib mesylate, cyclophosphamide, etoposide, filgrastim and 3 more |
| Enrollment | 126 |
| Start date | Jan 1, 2003 |
| Primary completion | Mar 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: